In this context, the inhibition of p44/42 MAPK activity achievable through MEK inhibition was explored as a potential strategy for cancers carrying KRAS mutations, drawing from their efficacy in treating BRAFV600-mutant melanoma [14, 15]. Here, KRAS is linked to cancer.